Srinivas Akkaraju - Net Worth and Insider Trading
Srinivas Akkaraju Net Worth
The estimated net worth of Srinivas Akkaraju is at least $428 Million dollars as of 2024-04-17. Srinivas Akkaraju is the Director of Chinook Therapeutics Inc and owns about 5,161,888 shares of Chinook Therapeutics Inc (KDNY) stock worth over $208 Million. Srinivas Akkaraju is the Director, 10% Owner of Scholar Rock Holding Corp and owns about 6,788,609 shares of Scholar Rock Holding Corp (SRRK) stock worth over $95 Million. Srinivas Akkaraju is also the Director, 10% Owner of Mineralys Therapeutics Inc and owns about 4,519,361 shares of Mineralys Therapeutics Inc (MLYS) stock worth over $55 Million. Besides these, Srinivas Akkaraju also holds Principia Biopharma Inc (PRNB) , Intercept Pharmaceuticals Inc (ICPT) , Syros Pharmaceuticals Inc (SYRS) , Seagen Inc (SGEN) , aTyr Pharma Inc (LIFE) , Aravive Inc (ARAV) . Details can be seen in Srinivas Akkaraju's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Srinivas Akkaraju has not made any transactions after 2023-12-21 and currently still holds the listed stock(s).
Transaction Summary of Srinivas Akkaraju
Srinivas Akkaraju Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Srinivas Akkaraju owns 21 companies in total, including Aduro Biotech Inc (ADRO) , Syros Pharmaceuticals Inc (SYRS) , and Intercept Pharmaceuticals Inc (ICPT) among others .
Click here to see the complete history of Srinivas Akkaraju’s form 4 insider trades.
Insider Ownership Summary of Srinivas Akkaraju
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
ADRO | Aduro Biotech Inc | 2020-10-05 | director |
SYRS | Syros Pharmaceuticals Inc | 2023-12-21 | director |
ICPT | Intercept Pharmaceuticals Inc | 2021-03-12 | director |
SGEN | Seagen Inc | 2020-05-05 | director |
ARAV | Aravive Inc | 2019-12-02 | director |
PRNB | Principia Biopharma Inc | 2018-09-18 | director |
LIFE | aTyr Pharma Inc | 2015-07-08 | director |
ZSPH | ZS Pharma Inc | 2015-12-17 | director |
ACRS | Aclaris Therapeutics Inc | 2015-10-06 | 10 percent owner |
SYBX | Synlogic Inc | 2015-09-30 | 10 percent owner |
ONCE | Spark Therapeutics Inc | 2015-01-29 | 10 percent owner |
OCGN | Ocugen Inc | 2014-12-02 | 10 percent owner |
ALIM | Alimera Sciences Inc | 2014-09-11 | 10 percent owner |
MEIP | MEI Pharma Inc | 2012-12-18 | 10 percent owner |
PRTK | Paratek Pharmaceuticals Inc | 2011-07-13 | 10 percent owner |
WWHC | W World Corp | 2011-01-05 | director |
KDNY | Chinook Therapeutics Inc | 2022-05-27 | director |
GRPH | Graphite Bio Inc | 2021-06-24 | 10 percent owner |
JYAC | Jiya Acquisition Corp | 2020-11-18 | director & 10 percent owner |
SRRK | Scholar Rock Holding Corp | 2023-10-16 | director |
MLYS | Mineralys Therapeutics Inc | 2023-02-14 | director & 10 percent owner |
Srinivas Akkaraju Latest Holdings Summary
Srinivas Akkaraju currently owns a total of 9 stocks. Among these stocks, Srinivas Akkaraju owns 5,161,888 shares of Chinook Therapeutics Inc (KDNY) as of May 27, 2022, with a value of $208 Million and a weighting of 48.66%. Srinivas Akkaraju owns 6,788,609 shares of Scholar Rock Holding Corp (SRRK) as of October 16, 2023, with a value of $95 Million and a weighting of 22.2%. Srinivas Akkaraju also owns 4,519,361 shares of Mineralys Therapeutics Inc (MLYS) as of February 14, 2023, with a value of $55 Million and a weighting of 12.73%. The other 6 stocks Principia Biopharma Inc (PRNB) , Intercept Pharmaceuticals Inc (ICPT) , Syros Pharmaceuticals Inc (SYRS) , Seagen Inc (SGEN) , aTyr Pharma Inc (LIFE) , Aravive Inc (ARAV) have a combined weighting of 16.42% among all his current holdings.
Latest Holdings of Srinivas Akkaraju
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
KDNY | Chinook Therapeutics Inc | 2022-05-27 | 5,161,888 | 40.39 | 208,488,656 |
SRRK | Scholar Rock Holding Corp | 2023-10-16 | 6,788,609 | 14.01 | 95,108,412 |
MLYS | Mineralys Therapeutics Inc | 2023-02-14 | 4,519,361 | 12.07 | 54,548,687 |
PRNB | Principia Biopharma Inc | 2018-09-18 | 383,480 | 100.05 | 38,367,174 |
ICPT | Intercept Pharmaceuticals Inc | 2021-03-12 | 663,809 | 19.00 | 12,612,371 |
SYRS | Syros Pharmaceuticals Inc | 2023-12-21 | 1,789,093 | 5.56 | 9,947,357 |
SGEN | Seagen Inc | 2020-05-05 | 40,168 | 228.74 | 9,188,028 |
LIFE | aTyr Pharma Inc | 2015-05-12 | 133,296 | 1.60 | 213,807 |
ARAV | Aravive Inc | 2019-12-02 | 607,881 | 0.04 | 24,376 |
Holding Weightings of Srinivas Akkaraju
Srinivas Akkaraju Form 4 Trading Tracker
According to the SEC Form 4 filings, Srinivas Akkaraju has made a total of 3 transactions in Chinook Therapeutics Inc (KDNY) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Chinook Therapeutics Inc is the acquisition of 570,000 shares on May 27, 2022, which cost Srinivas Akkaraju around $8 Million.
According to the SEC Form 4 filings, Srinivas Akkaraju has made a total of 1 transactions in Scholar Rock Holding Corp (SRRK) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Scholar Rock Holding Corp is the acquisition of 2,189,781 shares on October 16, 2023, which cost Srinivas Akkaraju around $15 Million.
According to the SEC Form 4 filings, Srinivas Akkaraju has made a total of 1 transactions in Mineralys Therapeutics Inc (MLYS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Mineralys Therapeutics Inc is the acquisition of 937,500 shares on February 14, 2023, which cost Srinivas Akkaraju around $15 Million.
More details on Srinivas Akkaraju's insider transactions can be found in the Insider Trading History of Srinivas Akkaraju table.Insider Trading History of Srinivas Akkaraju
- 1
Srinivas Akkaraju Trading Performance
GuruFocus tracks the stock performance after each of Srinivas Akkaraju's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Srinivas Akkaraju is 15.82%. GuruFocus also compares Srinivas Akkaraju's trading performance to market benchmark return within the same time period. The performance of stocks bought by Srinivas Akkaraju within 3 months outperforms 13 times out of 24 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Srinivas Akkaraju's insider trading performs compared to the benchmark.
Performance of Srinivas Akkaraju
Average Relative Return
-6.97%
Outperforming Transactions
41%
1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
---|---|---|---|---|---|---|
Relative Return(%) | 6 | 15.82 | 8.33 | -6.97 | 1.62 | -15.12 |
Relative Return to S&P 500(%) | 5.46 | 12.52 | 4.34 | -13.5 | -9.21 | -26.31 |
Srinivas Akkaraju Ownership Network
Ownership Network List of Srinivas Akkaraju
Ownership Network Relation of Srinivas Akkaraju
Srinivas Akkaraju Owned Company Details
What does Aduro Biotech Inc do?
Who are the key executives at Aduro Biotech Inc?
Srinivas Akkaraju is the director of Aduro Biotech Inc. Other key executives at Aduro Biotech Inc include director & President & CEO Eric Dobmeier , 10 percent owner Versant Voyageurs I, L.p. , and 10 percent owner Versant Voyageurs I Parallel, L.p. .
Aduro Biotech Inc (ADRO) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Aduro Biotech Inc (ADRO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aduro Biotech Inc (ADRO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Aduro Biotech Inc (ADRO)'s detailed insider trading history can be found in Insider Trading Tracker table.
Aduro Biotech Inc Insider Transactions
Srinivas Akkaraju Mailing Address
Above is the net worth, insider trading, and ownership report for Srinivas Akkaraju. You might contact Srinivas Akkaraju via mailing address: 565 Everett Avenue, Palo Alto Ca 94301.